This content appears to be an announcement or discussion about IT services for the healthcare sector broadcasted by News Channel Nebraska. However, without further context or detail, providing a comprehensive summary is not possible.
Startup OMass Secures $310M to Advance Drug for Rare Endocrine Disorder
OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But
